Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative project was to identify surrogate end points that could serve...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin J Am Soc Nephrol
Asıl Yazarlar: Thompson, Aliza, Carroll, Kevin, A. Inker, Lesley, Floege, Jürgen, Perkovic, Vlado, Boyer-Suavet, Sonia, W. Major, Rupert, I. Schimpf, Judith, Barratt, Jonathan, Cattran, Daniel C., S. Gillespie, Barbara, Kausz, Annamaria, W. Mercer, Alex, Reich, Heather N., H. Rovin, Brad, West, Melissa, Nachman, Patrick H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Nephrology 2019
Konular:
Feature
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6419287/
https://ncbi.nlm.nih.gov/pubmed/30635299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.08600718
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller